Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
作者信息
Albert J, Wahlberg J, Lundeberg J, Cox S, Sandström E, Wahren B, Uhlén M
机构信息
Department of Virology, National Bacteriological Laboratory, Stockholm, Sweden.
出版信息
J Virol. 1992 Sep;66(9):5627-30. doi: 10.1128/JVI.66.9.5627-5630.1992.
Abstract
The rate of reversion from azidothymidine (zidovudine; AZT) resistance was studied by direct sequencing of human immunodeficiency virus type 1 (HIV-1) virion RNA in sera from four patients who discontinued long-term treatment. Before cessation of treatment, all four patients harbored HIV-1 with multiple mutations reported to confer AZT resistance. In three patients, slow reversions of these mutations starting after 9, 9, and 18 months were detected. The slow reversions indicate that AZT-resistant HIV-1 variants are likely to have an unaltered replicative capacity and pathogenic potential. Furthermore, there were discrepancies between the in vivo RNA sequences and the sequences of virus isolates, indicating that the isolation procedure may select for nonrepresentative virus variants.
摘要
相似文献
1
Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
J Virol. 1992 Sep;66(9):5627-30. doi: 10.1128/JVI.66.9.5627-5630.1992.
2
Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
J Infect Dis. 1993 Feb;167(2):445-8. doi: 10.1093/infdis/167.2.445.
3
Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
Ann N Y Acad Sci. 1990;616:346-55. doi: 10.1111/j.1749-6632.1990.tb17855.x.
4
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
J Virol. 1992 Dec;66(12):7128-35. doi: 10.1128/JVI.66.12.7128-7135.1992.
5
Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):25-9. doi: 10.1073/pnas.90.1.25.
6
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Science. 1991 Sep 27;253(5027):1557-9. doi: 10.1126/science.1716788.
7
Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
J Med Virol. 1995 Jul;46(3):238-43. doi: 10.1002/jmv.1890460312.
8
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
Science. 1989 Dec 1;246(4934):1155-8. doi: 10.1126/science.2479983.
9
Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
J Gen Virol. 1993 Feb;74 ( Pt 2):223-8. doi: 10.1099/0022-1317-74-2-223.
10
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
Antimicrob Agents Chemother. 1993 Jul;37(7):1480-7. doi: 10.1128/AAC.37.7.1480.
引用本文的文献
1
Fitness Cost of Antiretroviral Drug Resistance Mutations on the Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure.
Pathogens. 2021 Nov 3;10(11):1425. doi: 10.3390/pathogens10111425.
2
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
PLoS One. 2012;7(2):e32055. doi: 10.1371/journal.pone.0032055. Epub 2012 Feb 23.
3
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
J Virol. 2004 Jan;78(2):603-11. doi: 10.1128/jvi.78.2.603-611.2004.
4
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
J Virol. 2001 Jan;75(2):595-602. doi: 10.1128/JVI.75.2.595-602.2001.
5
Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.
J Virol. 2000 Dec;74(23):10958-64. doi: 10.1128/jvi.74.23.10958-10964.2000.
6
Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.
J Virol. 2000 Jun;74(11):5357-62. doi: 10.1128/jvi.74.11.5357-5362.2000.
7
Use of multiple competitors for quantification of human immunodeficiency virus type 1 RNA in plasma.
J Clin Microbiol. 1998 Jul;36(7):1864-70. doi: 10.1128/JCM.36.7.1864-1870.1998.
8
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.
J Virol. 1998 Jun;72(6):5154-64. doi: 10.1128/JVI.72.6.5154-5164.1998.
9
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
J Virol. 1998 May;72(5):3773-8. doi: 10.1128/JVI.72.5.3773-3778.1998.
10
Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
J Virol. 1998 May;72(5):3520-3. doi: 10.1128/JVI.72.5.3520-3523.1998.
本文引用的文献
1
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
N Engl J Med. 1987 Jul 23;317(4):185-91. doi: 10.1056/NEJM198707233170401.
2
Biologic features of HIV-1 that correlate with virulence in the host.
Science. 1988 Apr 1;240(4848):80-2. doi: 10.1126/science.2832945.
3
Avoiding false positives with PCR.
Nature. 1989 May 18;339(6221):237-8. doi: 10.1038/339237a0.
4
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.
Cell. 1989 Sep 8;58(5):901-10. doi: 10.1016/0092-8674(89)90942-2.
5
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.
J Med Virol. 1989 Nov;29(3):170-5. doi: 10.1002/jmv.1890290305.
6
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
Science. 1989 Dec 1;246(4934):1155-8. doi: 10.1126/science.2479983.
7
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Science. 1989 Mar 31;243(4899):1731-4. doi: 10.1126/science.2467383.
8
Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers.
J Clin Microbiol. 1990 Jul;28(7):1560-4. doi: 10.1128/jcm.28.7.1560-1564.1990.
9
Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.
J Virol. 1991 Nov;65(11):6266-76. doi: 10.1128/JVI.65.11.6266-6276.1991.
10
Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing.
AIDS Res Hum Retroviruses. 1991 Dec;7(12):983-90. doi: 10.1089/aid.1991.7.983.
Zotero 插件